TriSalus Life Sciences (TLSI) Total Non-Current Liabilities (2020 - 2026)
TriSalus Life Sciences (TLSI) posted quarterly Total Non-Current Liabilities of $55.4 million for Q1 2026, up 3.54% year-over-year from $53.5 million in Q1 2025, and down 6.13% quarter-over-quarter from $59.0 million in Q4 2025.
TriSalus Life Sciences (TLSI) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
TriSalus Life Sciences' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $55.4 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 3.54% year-over-year to $55.4 million; the TTM figure through Mar 2026 stood at $55.4 million (up 3.54% YoY), while the FY2025 annual figure was $59.0 million, up 42.12% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $55.4 million, down from $59.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $59.0 million in Q4 2025, with the low at $10.8 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $38.2 million (2024), against an average of $35.0 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 227.97% in 2022, then decreased 2.71% in 2023.
- TriSalus Life Sciences' Total Non-Current Liabilities stood at $33.9 million in 2022, then retreated by 2.71% to $33.0 million in 2023, then climbed by 25.79% to $41.5 million in 2024, then surged by 42.12% to $59.0 million in 2025, then retreated by 6.13% to $55.4 million in 2026.
- Business Quant data shows TLSI's Total Non-Current Liabilities at $55.4 million in Q1 2026, $59.0 million in Q4 2025, and $58.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.51 Bn | 194.91 Bn | 7.27 Bn | - |
| 2 | Stryker | 129.96 Bn | 126.48 Bn | 4.50 Bn | 21.28 Bn |
| 3 | Medtronic | 120.18 Bn | 110.96 Bn | 6.41 Bn | 40.90 Bn |
| 4 | Boston Scientific | 74.28 Bn | 73.74 Bn | 3.85 Bn | 42.74 Bn |
| 5 | Edwards Lifesciences | 52.75 Bn | 48.50 Bn | 1.35 Bn | 2.57 Bn |
| 6 | Dexcom | 34.67 Bn | 32.73 Bn | 830.00 Mn | 3.68 Bn |
| 7 | GE HealthCare Technologies | 34.23 Bn | 32.12 Bn | 2.18 Bn | 23.89 Bn |
| 8 | Koninklijke Philips | 26.46 Bn | 23.14 Bn | 4.55 Bn | 9.07 Bn |
| 9 | Steris | 23.30 Bn | 22.82 Bn | 684.20 Mn | 3.44 Bn |
| 10 | TriSalus Life Sciences | 310.14 Mn | 263.85 Mn | 9.90 Mn | 49.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.58 Mn |
| Mar 31, 2026 | 55.43 Mn |
| Dec 31, 2025 | 59.05 Mn |
| Sep 30, 2025 | 58.19 Mn |
| Jun 30, 2025 | 53.24 Mn |
| Mar 31, 2025 | 53.54 Mn |
| Dec 31, 2024 | 41.55 Mn |
| Sep 30, 2024 | 40.10 Mn |
| Jun 30, 2024 | 47.65 Mn |
| Mar 31, 2024 | 38.23 Mn |
| Dec 31, 2023 | 33.03 Mn |
| Sep 30, 2023 | 19.65 Mn |
| Jun 30, 2023 | 14.78 Mn |
| Mar 31, 2023 | 13.41 Mn |
| Dec 31, 2022 | 33.95 Mn |
| Sep 30, 2022 | 11.36 Mn |
| Jun 30, 2022 | 10.99 Mn |
| Mar 31, 2022 | 10.83 Mn |
| Dec 31, 2021 | 10.35 Mn |
| Sep 30, 2021 | 9.45 Mn |